MTEC and BrightFocus Foundation are jointly funding up to $500,000 for research that will enable the advancement of candidate drugs for the treatment of repeated mild traumatic brain injury (mTBI).
In the last two decades, there have been approximately 420,000 documented incidents of U.S. military members sustaining at least one traumatic brain injury (TBI). TBI has been shown to increase long-term mortality and reduce life expectancy. Furthermore, studies have shown that suffering from repeated mTBIs, or a single moderate or severe TBI increases the risk of developing pathological changes to the brain that are characteristic of Alzheimer’s disease (AD), an irreversible, progressive disease that negatively impacts memory, cognitive ability, and behavior.
BrightFocus Foundation is a nonprofit that funds scientific research to slow, prevent, treat, and ultimately end Alzheimer’s disease, macular degeneration, and glaucoma. Since its founding, it has awarded more than $224 million in research to help eradicate diseases of mind and sight.
MTEC’s mission is to accelerate the translation of medical technologies into solutions that prevent and treat injuries and restore the health of United States military personnel and veterans. MTEC uses a simplified contracting vehicle (the Other Transaction Agreement (OTA)), which enables federal sponsors to quickly and openly partner with MTEC members in a more transparent manner.
BrightFocus Foundation and MTEC have come together to address a critical need in TBI research. Repeated mTBIs – which are common in contact sports and military settings – have been indicated as a risk factor in developing various neurodegenerative diseases. This research has the potential to impact service members on the front line, as well as our mothers, fathers, sons and daughters.
Despite numerous clinical trials on potential therapies, there is no FDA-approved drug therapy for the treatment of TBI. This co-funded research – the first of its kind for MTEC – seeks to advance candidate drugs into human clinical trials. The ultimate objective of this work is to develop a drug therapy for the treatment of repeated mTBI that will benefit both military and civilian populations.